Juno Therapeutics, Inc. Company Profile

03:49 EDT 20th March 2018 | BioPortfolio

About Opus Bio

News Articles [918 Associated News Articles listed on BioPortfolio]

Juno Therapeutics Spinout Raises $90M

JW Therapeutics, a clinical stage biopharma company founded by Juno Therapeutics and WuXi AppTec Group, has closed a Series A financing worth $90 million.

Celgene To Buy Juno Therapeutics In $9 Bln Deal; Reaffirms 2020 Targets

SUMMIT (dpa-AFX) - Celgene Corp. (CELG) said Monday that it agreed to buy Juno Therapeutics Inc. (JUNO) for $87 per share in cash or an aggregate of about $9 billion, net of cash and marketable se...

Celgene Finalises Acquisition Of Juno Therapeutics

SUMMIT (dpa-AFX) - Celgene Corp. (CELG) Tuesday said it completed the acquisition of Juno Therapeutics, Inc. The shares of Juno will no longer be trading on the NASDAQ.Celgene offered $9 billion o...

Celgene signs $9bn acquisition deal with Juno Therapeutics

Celgene has entered a definitive merger agreement to acquire US-based biopharmaceutical firm Juno Therapeutics for $87 per share, totalling approximately...Read More... The post Celgene signs $9bn acq...

Celgene Corporation to Acquire Juno Therapeutics, Inc.

NewsCelgene Corporation and Juno Therapeutics, Inc. today announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Juno.

Juno Therapeutics signs a trio of licensing deals

USA-based Juno Therapeutics rose 4% in pre-market trading, after it announced three license agreements…

STAT Plus: Biotech’s comeback company of the year: Juno Therapeutics

After a disastrous clinical trial, Juno Therapeutics has rebounded with strong data from a CAR-T cancer treatment. The startup looks like a tempting acquisition target.

Celgene to Acquire Juno Therapeutics for $9 Billion, Advancing Global Leadership in Cellular Immunotherapy

SUMMIT, N.J. & SEATTLE–(BUSINESS WIRE)–Celgene Corporation (NASDAQ:CELG) and Juno Therapeutics, Inc. (NASDAQ:JUNO) today announced the signing of a definitive merger agreement in which...

PubMed Articles [404 Associated PubMed Articles listed on BioPortfolio]

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Eyes on New Product Development: Preclinical Research.

Introduction to Volume 2 of JOPT Special Issue.

Introduction to Volume 1 of JOPT Special Issue.

Clinical Trials [135 Associated Clinical Trials listed on BioPortfolio]

Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

This study will provide long-term follow-up for patients who have received treatment with a Juno CAR T-cell product in a Juno-sponsored clinical trial. In this study, patients will be foll...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Companies [1200 Associated Companies listed on BioPortfolio]

Juno Therapeutics, Inc.

About Opus Bio

Juno Online Services, Inc.

Juno is a nationwide ISP offering consumers a choice of 3 low price dial up Internet access options to meet their budget and personal Internet access needs. Juno Platinum Internet service offers a val...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Juno Therapeutics, Inc." on BioPortfolio

We have published hundreds of Juno Therapeutics, Inc. news stories on BioPortfolio along with dozens of Juno Therapeutics, Inc. Clinical Trials and PubMed Articles about Juno Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Juno Therapeutics, Inc. Companies in our database. You can also find out about relevant Juno Therapeutics, Inc. Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record